Article (Scientific journals)
Quels benefices antitumoraux attendre de la metformine ?
Beck, Emmanuel; SCHEEN, André
2013In Annales d'Endocrinologie, 74 (2), p. 137-47
Peer Reviewed verified by ORBi
 

Files


Full Text
benefices antitumoraux metformine.pdf
Author postprint (322.37 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
type 2 diabetes; metformin; cancer
Abstract :
[en] With the better management of cardiovascular risk factors, cancer plays an increasing role in the causes of death among patients with type 2 diabetes. Numerous epidemiological cohort and case-control studies showed that type 2 diabetes is a risk factor for cancer and that metformin therapy is associated with a significant reduction in the incidence of cancer and cancer-related death when compared to other glucose-lowering agents (sulfonylureas, insulin). Such beneficial effect is observed almost whatever the type of cancer, but seems to be more prominent in case of gastrointestinal and breast cancers. Several studies showed a significant relationship between the amplitude of the protection against cancer, on the one hand, and the daily dose of metformin and the duration of exposure, on the other hand. In general, the protective effect was more evident in observational cohort studies (however, more exposed to bias due to confounding factors) than in case-control studies. Several meta-analyses recently confirmed that metformin therapy reduces the incidence of cancers and cancer-related mortality. However, the results of the rather rare controlled clinical trials available are not conclusive, but none of them was performed with the objective to specifically assess cancer risk. Considering all promising clinical information in patients with type 2 diabetes, further clinical trials are currently ongoing with the aim of assessing the role of metformin in oncology, independently of the presence of diabetes.
Disciplines :
Pharmacy, pharmacology & toxicology
Oncology
Author, co-author :
Beck, Emmanuel
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
French
Title :
Quels benefices antitumoraux attendre de la metformine ?
Alternative titles :
[en] Which anti-tumour benefits to be expected from metformin?
Publication date :
2013
Journal title :
Annales d'Endocrinologie
ISSN :
0003-4266
Publisher :
Elsevier Masson, Paris, France
Volume :
74
Issue :
2
Pages :
137-47
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
Available on ORBi :
since 23 August 2013

Statistics


Number of views
101 (2 by ULiège)
Number of downloads
465 (1 by ULiège)

Scopus citations®
 
8
Scopus citations®
without self-citations
1
OpenCitations
 
6

Bibliography


Similar publications



Contact ORBi